Loading clinical trials...
Loading clinical trials...
This is a randomized double-blind placebo-controlled phase 3 clinical trial to further validate the effectiveness and safety of Shugan Jieyu Capsules in treating generalized anxiety disorder.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sichuan Jishengtang Pharmaceutical Co., Ltd.
NCT06804525 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more
NCT07429578 · Generalized Anxiety Disorder (GAD), Chronic Insomnia
NCT06661460 · ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Specific Phobia, and more
NCT05467683 · Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, and more
NCT06846320 · Generalized Anxiety Disorder (GAD)
Beijing Anding Hospital Affiliated to Capital Medical University
Beijing
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions